Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFaron Pharma Share News (FARN)

Share Price Information for Faron Pharma (FARN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 150.00
Bid: 140.00
Ask: 160.00
Change: 0.00 (0.00%)
Spread: 20.00 (14.286%)
Open: 150.00
High: 150.00
Low: 150.00
Prev. Close: 150.00
FARN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON AIM WINNERS & LOSERS: CPPGroup Earnings To Beat Forecasts

Mon, 18th Jan 2021 10:41

(Alliance News) - The following stocks are the leading risers and fallers on AIM on Monday.

----------

AIM WINNERS

----------

CPPGroup, up 46% at 478.00 pence. The insurance and financial services company said earnings for 2020 are expected to surpass market consensus, with the firm expecting 2020 earnings before interest, tax, depreciation, and amortization of between GBP7.1 million to GBP7.3 million, ahead of market forecasts of GBP6.4 million.

----------

Faron Pharmaceuticals, up 22% at 337.56 pence. The biopharmaceutical said the US Department of Defense has chosen the HIBISCUS Study to receive USD6.1 million of funding from the Coronavirus Aid, Relief & Economic Security Act. The phase II/III HIBISCUS trial will assess Traumakine, Faron's IV IFN beta-1a, for the treatment of hospitalised Covid-19 patients in the US.

----------

Mosman Oil & Gas, up 22% at 0.214 pence. The Australia and US-focused oil and gas explorer confirmed the completion of the sale of the Welch Project, in Texas, for USD420,000.

----------

Augean, up 10% at 206.25 pence. The waste management company said it expects to report an adjusted pretax profit for 2020 at least in line with the year before, despite the decline of its North Sea business and the ongoing Covid-19 pandemic. In 2019, Augean's adjusted pretax profit was GBP19.2 million.

----------

AIM LOSERS

----------

Velocys, down 26% at 7.64 pence. The sustainable fuels technology company said Shell International Petroleum has withdrawn from the Altalto Joint Development agreement. Velocys and British Airways will continue to work to secure finance for the Altalto Immingham plant, and will continue talks with potential finance sources.

----------

SEC Newgate, down 12% at 42.50 pence. The public relations firm said its two largest UK agencies, SEC Newgate UK - Newgate Communications - and Newington Communications, will merge and rebrand as SEC Newgate UK. As part of this, SEC Newgate will increase its stake in Newington to 100% from 60%, paying GBP420,799 for the 40% minority stake it did not already own.

----------

Remote Monitored Systems, down 8.7% at 2.74 pence. The data collection and surveying firm said the last test for its 4-ply mask, the biocompatibility test, has been delayed and is now expected to be completed in the next week. The mask manufacturing machine arrived from Lemu, as expected, and has been installed in Nottingham's BioCity, with work beginning this week to commission the machine and commence production.

----------

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
12 Feb 2021 10:40

Faron Pharmaceuticals Raises EUR15 Million In Share Placing

Faron Pharmaceuticals Raises EUR15 Million In Share Placing

Read more
11 Feb 2021 17:49

IN BRIEF: Faron Pharmaceuticals Plans To Raise EUR15 Million

IN BRIEF: Faron Pharmaceuticals Plans To Raise EUR15 Million

Read more
26 Jan 2021 11:45

IN BRIEF: Faron Pharmaceuticals Gets US Approval For Covid-19 Trial

IN BRIEF: Faron Pharmaceuticals Gets US Approval For Covid-19 Trial

Read more
20 Jan 2021 15:12

Faron Notes "Remarkable" Observations From Bexmarilimab Trial

Faron Notes "Remarkable" Observations From Bexmarilimab Trial

Read more
20 Jan 2021 10:40

LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal

LONDON AIM WINNERS & LOSERS: Sabien Sinks On Ptarmigan Deal Withdrawal

Read more
18 Jan 2021 10:22

Faron Pharmaceuticals Gets USD6 Million Funding For Covid-19 Treatment

Faron Pharmaceuticals Gets USD6 Million Funding For Covid-19 Treatment

Read more
23 Nov 2020 21:12

IN BRIEF: Four Cohorts In Faron Pharmaceuticals Study Move To Part 3

IN BRIEF: Four Cohorts In Faron Pharmaceuticals Study Move To Part 3

Read more
24 Sep 2020 14:02

IN BRIEF: Faron Pharmaceuticals Says Virus Barely Affected Operations

IN BRIEF: Faron Pharmaceuticals Says Virus Barely Affected Operations

Read more
17 Sep 2020 16:03

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
18 Aug 2020 11:55

Faron Gets EUR2.5 Million Loan Guarantee For Traumakine Production

Faron Gets EUR2.5 Million Loan Guarantee For Traumakine Production

Read more
15 Jun 2020 13:05

IN BRIEF: Faron Pharma Receives EUR2.1 Million Loan To Develop Product

IN BRIEF: Faron Pharma Receives EUR2.1 Million Loan To Develop Product

Read more
15 Jun 2020 12:44

Faron Pharmaceuticals gets Finnish state loan for manufacturing process

(Sharecast News) - Clinical-stage biopharmaceutical company Faron Pharmaceuticals announced plans to initiate a new "state-of-the-art" process for the manufacturing of 'interferon' (IFN) beta-1a on Monday.

Read more
11 Jun 2020 13:51

Faron receives EIC grant for 'MATINS' study

(Sharecast News) - Clinical-stage biopharmaceuticals company Faron Pharmaceuticals has been selected to receive a €2.5m (£2.24m) grant from the European Innovation Council's 'Accelerator' pilot scheme, it announced on Thursday, to progress the 'MATINS' study, and related business activities.

Read more
11 Jun 2020 13:23

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

UK TRADING UPDATE SUMMARY: Churchill China Sales Hit By Virus

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.